Similar companies
| Company | Business Outlook | |
|---|---|---|
 |
AmgenAMGN |
77 1.3% |
 |
Gilead SciencesGILD |
57 0% |
 |
Catalyst PharmaceuticalsCPRX |
100 0% |
 |
Inovio PharmaceuticalsINO |
23 0% |
 |
Anavex Life SciencesAVXL |
0 0% |
Month over Month
Employee view on business outlook (0 - 100)
| Oct 2024 | 66 | |
| Sep 2024 | 64 | |
| Aug 2024 | 63 | |
| Jul 2024 | 63 |
How do employees feel about the future at Karyopharm Therapeutics?
The Business Outlook at Karyopharm Therapeutics is neutral, according to employees. The average rating, aggregated from the top review sites in the US, of 63 out of 100 is decent. The rating is down, compared to previous month.
Analyzing Business Outlook, how is Karyopharm Therapeutics performing compared to its industry peers?
Karyopharm Therapeutics overperforms a majority of its industry peers when it comes to Business Outlook, ranking in the 63rd percentile.
How has the business outlook at Karyopharm Therapeutics changed over the last couple of months
There has been no meaningful change in the business outlook amongst employees at Karyopharm Therapeutics.
Why is it important to track the business outlook at Karyopharm Therapeutics?
Tracking a company's business outlook is important as a positive outlook can indicate future growth and profitability and attract new talent, while a negative outlook can discourage talent and imply demotivated employees. Additionally, data shows that companies with a high business outlook tend to perform better on the stock market compared to those with a lower business outlook.
Sign up and get more insights on the business outlook at Karyopharm Therapeutics.
